People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aktis Oncology, Inc. | — | Biotechnology | Series D+ | $175.0M | $1.8B | 2024 |
| NextPoint Therapeutics, Inc. | — | Biotechnology | Series C | $122.5M | $444.1M | 2022 |
| HotKnot Therapeutics, Inc. | — | Biotechnology | Series C | $72.0M | $2.3B | 2021 |
Matthew Roden at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Roden on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 2 | 12 |
| Ansbert Gadicke | 1 | 7 |
| R. Jacob Vogelstein | 1 | 6 |
| Helen S. Kim | 1 | 6 |
| Paulina Hill | 1 | 5 |
| Detlev Biniszkiewicz | 1 | 4 |
| Oleg Nodelman | 1 | 3 |
| Axel Hoos | 1 | 2 |
| Brian Goodman | 1 | 2 |
| Rakhshita Dhar | 1 | 2 |
| Andrew S. Levin | 1 | 2 |
| Lloyd M. Segal | 1 | 1 |
| Shulamit S. Ron-Bigger | 1 | 1 |
| Ken S. Herrmann | 1 | 1 |
| Lloyd S. Segal | 1 | 1 |
| Ivan Cheung | 1 | 1 |
| Paul Conrad | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.